Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation
Kim H, Yi N, Lee J, Kim J, Moon M, Jeong J, Lee J, You T, Suh S, Park M, Choi Y, Hong G, Lee H, Lee K, Suh K. Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation. Clinical And Molecular Hepatology 2014, 20: 291-299. PMID: 25320733, PMCID: PMC4197178, DOI: 10.3350/cmh.2014.20.3.291.Peer-Reviewed Original ResearchConceptsDose of mycophenolate mofetilReduced dose of mycophenolate mofetilLiving-donor liver transplantationMycophenolate mofetilReduced doseSide effectsProtocol biopsiesPost-LDLTLiver transplantationLower doses of mycophenolate mofetilLow levels of tacrolimusAdult living-donor liver transplantationRejection-free survival ratesExcellent short-term outcomesLevels of tacrolimusProspective pharmacokinetic studyRecommended therapeutic rangePostoperative day 7Area under the curveAssociated with lower blood levelsShort-term outcomesYears post-LDLTMonths post-LDLTLow blood levelsAUC(0-12
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply